|Bid||2.10 x 2200|
|Ask||2.35 x 3000|
|Day's Range||2.24 - 2.35|
|52 Week Range||1.70 - 3.60|
|PE Ratio (TTM)||25.56|
|Earnings Date||Aug 7, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.58|
LONDON, UK / ACCESSWIRE / May 17, 2018/ If you want a free Stock Review on BLRX sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com evaluates Aratana Therapeutics Inc. (NASDAQ: PETX), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), BioDelivery Sciences International Inc. (NASDAQ: BDSI), and BioLine Rx Ltd (NASDAQ: BLRX).
BioDelivery Sciences International, Inc. (BDSI) today announced that it has entered into an agreement with an affiliate of Broadfin Capital LLC (Broadfin), a large BDSI stockholder, to reconstitute BDSI’s Board of Directors and to significantly strengthen BDSI’s financial position. The closing of this agreement is subject to and effective upon the closing of BDSI’s $50 million equity financing announced earlier today.
The Series B Stock is being sold for $10,000 per share, and each share of Series B Stock will be convertible into a number of shares of BDSI common stock determined by dividing $10,000 by $1.80. Although BDSI will receive the proceeds of the offering at closing, the Series B Stock will not be convertible into common stock until BDSI receives stockholder approval of the transaction for Nasdaq Stock Market purposes as well as stockholder approval of an increase in BDSI’s authorized shares of common stock.
On a per-share basis, the Raleigh, North Carolina-based company said it had a loss of 18 cents. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
BELBUCA ® Net Revenues Increased 76% Over 1 Q17 Achieved Significant Prescription Growth Increase of 55% for BELBUCA in 1 Q18 vs 1 Q17 Achieved Company Total Net Revenue of $11.3 Million for 1 Q18 Addition ...
Endocyte (ECYT) is expected to provide updates on pipeline candidates when it reports first-quarter 2018 results on May 9 after the market closes.
Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).
BioDelivery Sciences International, Inc. (BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine, announced today that Herm Cukier has been appointed Chief Executive Officer and a member of the Board of Directors of BioDelivery Sciences effective May 8, 2018. Former President and Chief Executive Officer, Dr. Mark A. Sirgo, will continue his role as Vice Chairman of the Board of Directors and, along with current President Scott Plesha, will work closely with Mr. Cukier in the transition of responsibilities. Herm will be introduced at the upcoming BDSI earnings call scheduled for Thursday, May 10, at 4:30 PM Eastern Time.
BDSI will present its recommendation with respect to the election of directors in its proxy statement to be filed with the Securities and Exchange Commission (the “SEC”). The 2018 Annual Meeting has not yet been scheduled and shareholders of BDSI need not take any action at this time. BioDelivery Sciences International, Inc. (BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.
RALEIGH, N.C., April 30, 2018-- BioDelivery Sciences International, Inc., a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that it will report ...
NEW YORK, April 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
BioDelivery Sciences (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
From BioDelivery Sciences International to Red Hat, insiders at Triangle companies raked in millions in the first three months of 2018, public records show.
Stock Monitor: BioDelivery Sciences Intl. Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 21, 2018 / Active-Investors.com has just released a free research report on Dova Pharmaceuticals, Inc. ...
BioDelivery (BDSI) reports wider-than-expected loss in Q4. However, revenues surpass estimates and increase substantially year over year.
BDSI reported net revenue of $62.0 million for 2017, compared to $15.5 million for the year prior. "2017 was an important year for BDSI and one of great change," said Scott Plesha, president of BDSI, on the company's quarterly and full-year financial results call Thursday afternoon.
Raleigh's BioDelivery Sciences International quadrupled revenue in 2017 and landed a new contract with Humana after reacquiring pain management drug Belbuca from Endo Pharmaceuticals at the beginning of last year.
In a release issued under the same headline earlier today by BioDelivery Sciences International, Inc., please note that in the second bullet of the Corporate section, the end date of the non-exclusive ...
The Raleigh, North Carolina-based company said it had a loss of 29 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Full-year 2017 net revenue of $62.0 million vs. $15.5 million in 2016. BELBUCA ® fourth quarter 2017 net revenue of $9.4 million vs. $6.4 million in third quarter; an increase of 47%. BELBUCA prescription ...